Microarray expression profile of long non-coding RNAs in EGFR-TKIs resistance of human non-small cell lung cancer

Oncology Reports

Volumn 33, Issue 2, 2015, Pages 833-839

  Cheng, Ningning ^a   Li, Xuefei ^a   Zhao, Chao ^a   Ren, Shengxiang ^a   Chen, Xiaoxia ^a   Cai, Weijing ^a   Zhao, Mingchuan ^a   Zhang, Yishi ^a   Li, Jiayu ^a   Wang, Qi ^a   Zhou, Caicun ^a  

^a TONGJI UNIVERSITY   (China)

Author keywords

Drug resistance; EGFR TKIs; Long non coding RNAs; Non small cell lung cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; LONG UNTRANSLATED RNA; PROTEIN KINASE INHIBITOR; RNA;

APOPTOSIS; CELL PROLIFERATION; CLUSTER ANALYSIS; DNA MICROARRAY; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LUNG TUMOR; METABOLISM; NON SMALL CELL LUNG CANCER; NUCLEIC ACID HYBRIDIZATION; POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CLUSTER ANALYSIS; DRUG RESISTANCE, NEOPLASM; ERBB RECEPTORS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; PROTEIN KINASE INHIBITORS; RNA; RNA, LONG NONCODING;

EID: 84938892924     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3643     Document Type: Article

References (36)

1. Zhang Z, Lee JC, Lin L, et al: Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet 44: 852-860, 2012.
2. Zhou C, Wu YL, Chen G, et al: Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12: 735-742, 2011.
3. Bar J and Onn A: Overcoming molecular mechanisms of resistance to first-generation epidermal growth factor receptor tyrosine kinase inhibitors. Clin Lung Cancer 13: 267-279, 2012.
4. Turke AB, Zejnullahu K, Wu YL, et al: Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell 17: 77-88, 2010.
5. Bean J, Brennan C, Shih JY, et al: MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 104: 20932-20937, 2007.
6. Qiu M, Xu Y, Yang X, et al: CCAT2 is a lung adenocarcinoma-specific long non-coding RNA and promotes invasion of non-small cell lung cancer. Tumour Biol 35: 5375-5380, 2014.
7. WAF1/CIP1 expression. PLoS One 8: e77293, 2013.
8. Gutschner T, Hämmerle M, Eissmann M, et al: The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res 73: 1180-1189, 2013.
9. Liu XH, Liu ZL, Sun M, et al: The long non-coding RNA HOTAIR indicates a poor prognosis and promotes metastasis in non-small cell lung cancer. BMC Cancer 13: 464, 2013.
10. Takahashi K, Yan I, Haga H and Patel T: Long noncoding RNA in liver diseases. Hepatology 60: 744-753, 2014.
11. Zhao J and Lawless MW: Long noncoding RNAs and their role in the liver cancer axis. Nat Rev Gastroenterol Hepatol: Nov 19, 2013 (Epub ahead of print). doi: 10.1038/nrgastro.2013.87-c1.
12. Ren S, Wang F, Shen J, et al: Long non-coding RNA metastasis associated in lung adenocarcinoma transcript 1 derived miniRNA as a novel plasma-based biomarker for diagnosing prostate cancer. Eur J Cancer 49: 2949-2959, 2013.
13. Iacoangeli A, Lin Y, Morley EJ, et al: BC200 RNA in invasive and preinvasive breast cancer. Carcinogenesis 25: 2125-2133, 2004.
14. Svoboda M, Slyskova J, Schneiderova M, et al: HOTAIR long non-coding RNA is a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients. Carcinogenesis 35: 1510-1515, 2014.
15. Yuan JH, Yang F, Wang F, et al: A long noncoding RNA activated by TGF-β promotes the invasion-metastasis cascade in hepatocellular carcinoma. Cancer Cell 25: 666-681, 2014.
16. Tsang WP and Kwok TT: Riboregulator H19 induction of MDR1-associated drug resistance in human hepatocellular carcinoma cells. Oncogene 26: 4877-4881, 2007.
17. Tsang WP, Wong TW, Cheung AH, et al: Induction of drug resistance and transformation in human cancer cells by the noncoding RNA CUDR. RNA 13: 890-898, 2007.
18. Jiang M, Huang O, Xie Z, et al: A novel long non-coding RNA-ARA: adriamycin resistance-associated. Biochem Pharmacol 87: 254-283, 2014.
19. Yang Y, Li H, Hou S, et al: The noncoding RNA expression profile and the effect of lncRNA AK126698 on cisplatin resistance in non-small-cell lung cancer cell. PLoS One 8: e65309, 2013.
20. Gainor JF and Shaw AT: Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol 31: 3987-3996, 2013.
21. Zhang EB, Yin DD, Sun M, et al: P53-regulated long non-coding RNA TUG1 affects cell proliferation in human non-small cell lung cancer, partly through epigenetically regulating HOXB7 expression. Cell Death Dis 5: e1243, 2014.
22. Hauptman N and Glavaè D: Long non-coding RNA in cancer. Int J Mol Sci 14: 4655-4669, 2013.
23. Li H, Schmid-Bindert G, Wang D, et al: Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines. Adv Med Sci 56: 275-284, 2011.
24. Sordella R, Bell DW, Haber DA and Settleman J: Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305: 1163-1167, 2004.
25. Ng KP, Hillmer AM, Chuah CT, et al: A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med 18: 521-528, 2012.
26. Li Z, Zhou S, Zhang L, et al: BIM induction of apoptosis triggered by EGFR-sensitive and resistance cell lines of non-small-cell lung cancer. Med Oncol 28: 572-577, 2011.
27. Yang F, Zhang L, Huo XS, et al: Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans. Hepatology 54: 1679-1689, 2011.
28. Xia L, Huang W, Tian D, et al: Overexpression of forkhead box C1 promotes tumor metastasis and indicates poor prognosis in hepatocellular carcinoma. Hepatology 57: 610-624, 2013.
29. Wang J, Ray PS, Sim MS, et al: FOXC1 regulates the functions of human basal-like breast cancer cells by activating NF-κB signaling. Oncogene 31: 4798-4802, 2012.
30. Uramoto H, Iwata T, Onitsuka T, et al: Epithelial-mesenchymal transition in EGFR-TKI acquired resistant lung adenocarcinoma. Anticancer Res 30: 2513-2517, 2010.
31. Bryant JL, Britson J, Balko JM, et al: A microRNA gene expression signature predicts response to erlotinib in epithelial cancer cell lines and targets EMT. Br J Cancer 106: 148-156, 2012.
32. Cufi S, Bonavia R, Vazquez-Martin A, et al: Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo. Sci Rep 3: 2459, 2013.
33. Wu ZZ, Sun NK and Chao CC: Knockdown of CITED2 using short-hairpin RNA sensitizes cancer cells to cisplatin through stabilization of p53 and enhancement of p53-dependent apoptosis. J Cell Physiol 226: 2415-2428, 2011.
34. Samatov TR, Tonevitsky AG and Schumacher U: Epithelial-mesenchymal transition: focus on metastatic cascade, alternative splicing, non-coding RNAs and modulating compounds. Mol Cancer 12: 107, 2013.
35. Ying L, Chen Q, Wang Y, et al: Upregulated MALAT-1 contributes to bladder cancer cell migration by inducing epithelial-to-mesenchymal transition. Mol Biosyst 8: 2289-2294, 2012.
36. Sequist LV, Waltman BA, Dias-Santagata D, et al: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med 3: 75ra26, 2011.